Table 4.
Geometric means and 95% CI of cardiometabolic and endocrine biomarkers by quartiles of moderate-to-vigorous physical activity measured by accelerometer (mins/day), Women’s Lifestyle Validation Studies, United States, 2010–2012.
| Quartiles | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 (median=0) | 2 (median = 5.1) | 3 (median=16.0) | 4 (median=37.5) | P-trend | |||||
| Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | ||
| Pro-Insulin (pmol/L), n=470 | |||||||||
| Model 1a | 21 | 19.3, 22.8 | 17.4 | 15.8, 19.1 | 18.1 | 16.3, 20.1 | 15.6 | 14, 17.4 | 0.0004 |
| Model 2b | 19.6 | 18.1, 21.2 | 17.4 | 15.9, 19 | 19 | 17.2, 21 | 16.7 | 15, 18.5 | 0.07 |
| C-peptide (ng/ml), n=525 | |||||||||
| Model 1a | 6.85 | 6.68, 7.02 | 6.54 | 6.37, 6.71 | 6.5 | 6.32, 6.7 | 6.34 | 6.15, 6.52 | 0.0005 |
| Model 2b | 6.7 | 6.54, 6.86 | 6.54 | 6.38, 6.7 | 6.59 | 6.41, 6.78 | 6.45 | 6.28, 6.64 | 0.11 |
| Insulin (mU/ml), n=453 | |||||||||
| Model 1a | 8.05 | 7.2, 9 | 6.98 | 6.18, 7.89 | 6.92 | 6, 7.97 | 5.51 | 4.76, 6.37 | 0.0002 |
| Model 2b | 7.23 | 6.52, 8.01 | 7.06 | 6.33, 7.88 | 7.46 | 6.56, 8.48 | 6.01 | 5.27, 6.87 | 0.044 |
| IGFBP-3 (μg/ml), n=524 | |||||||||
| Model 1a | 3.7 | 3.57, 3.83 | 3.68 | 3.54, 3.83 | 3.75 | 3.59, 3.92 | 3.77 | 3.61, 3.94 | 0.40 |
| Model 2b | 3.72 | 3.58, 3.86 | 3.68 | 3.54, 3.83 | 3.74 | 3.58, 3.91 | 3.76 | 3.59, 3.93 | 0.61 |
| IGF-1 (ng/ml), n=524 | |||||||||
| Model 1a | 101 | 96, 106 | 104 | 98, 110 | 107 | 100, 114 | 109 | 103, 116 | 0.07 |
| Model 2b | 102 | 97, 108 | 104 | 98, 110 | 106 | 99, 113 | 108 | 101, 115 | 0.24 |
| Adiponectin (μg/ml), n=526 | |||||||||
| Model 1a | 11.4 | 10.4, 12.6 | 13.1 | 11.9, 14.5 | 12.2 | 10.8, 13.6 | 14.9 | 13.3, 16.6 | 0.003 |
| Model 2b | 12.6 | 11.5, 13.7 | 13.1 | 11.9, 14.4 | 11.5 | 10.3, 12.8 | 13.7 | 12.4, 15.3 | 0.34 |
| Leptin (ng/ml), n=524 | |||||||||
| Model 1a | 37.8 | 34.2, 41.8 | 30.3 | 27.2, 33.7 | 29.5 | 26.2, 33.3 | 22.5 | 19.9, 25.3 | <.0001 |
| Model 2b | 31.5 | 29.1, 34 | 30.3 | 28, 32.9 | 32.9 | 30, 36 | 26.1 | 23.8, 28.5 | 0.004 |
| Leptin-sR (ng/ml), n=524 | |||||||||
| Model 1a | 28.2 | 27, 29.5 | 29.8 | 28.4, 31.2 | 30.1 | 28.6, 31.8 | 34.3 | 32.6, 36.2 | <.0001 |
| Model 2b | 29.9 | 28.7, 31.1 | 29.7 | 28.5, 31 | 29.2 | 27.8, 30.6 | 32.8 | 31.3, 34.4 | 0.003 |
Abbreviations: mins, minutes; IGFBP-3, insulin-like growth factor binding protein 3; IGF-1, insulin-like growth factor 1; Leptin-sR, leptin soluble receptor.
Model 1: Adjusted for age (continuous), Caucasian (yes/no), age at menopause (continuous), age at menarche (<12, 12, 13, 14+ years), parity and age at first birth (nulliparous, 1–2 children at <25 y at first birth, 1–2 children at 25+ y at first birth, 3+ children at < 25 y at first birth, 3+ children at 25+ y at first birth), postmenopausal status and post-menopausal hormone use (premenopausal, never, past, current use), smoking status (never, past, current 1–14 cigs/day, current 15+ cigs/day), alcohol intake (0, 0,1 – <5, 5 – <15, 15+ g/day), multivitamin use (yes.no), family history of cancer (yes/no), caffeine intake (quartiles), total fiber intake (quartiles) and total accelerometer wear time (hours/day, continuous).
Model 2: Model 1 + adjusted for body mass index (kg/m2, continuous).